Real World Evidence (RWE) 101 – The Impact of GDPR on RWE Research
The General Data Protection Regulation (GDPR) is a regulation in EU law on data protection and privacy for all individuals within the European Union (EU) and the European Economic Area (EEA). Its implementation in May 2018 has had a significant impact on research, particularly in the context of real-world evidence (RWE).
RWE refers to data collected outside of the traditional clinical trial setting, such as electronic health records (EHRs), claims data, and patient-generated data. RWE is increasingly being used to support regulatory decisions and to inform clinical practice. However, the use of RWE must comply with GDPR, which has implications for the collection, processing, and use of personal data in research.
Under GDPR, personal data must be collected and processed lawfully, fairly, and transparently, and individuals have the right to be informed about how their data is being used. This means that researchers must obtain explicit and informed consent from individuals to use their personal data for research purposes. In addition, the data must be pseudonymized or anonymized to protect individuals’ privacy.
GDPR has also increased the administrative burden for researchers, who must ensure that their data management practices are compliant with GDPR. This includes developing and implementing policies and procedures for data protection, privacy, and security, as well as appointing a Data Protection Officer to oversee data management activities.
Overall, GDPR has had a positive impact on research by increasing transparency and protecting the privacy of individuals whose data is used in research. However, compliance with GDPR can be challenging, particularly in the context of RWE, where large volumes of data are collected from multiple sources. It is essential for researchers to work closely with data protection and privacy experts to ensure that their research practices are compliant with GDPR.
Share this story...
Real World Evidence (RWE) 101 – ICH GCP (R3) – Real World Evidence Context
RWE 101 - ICH GCP (R3) - Real World Evidence Context Revision 2 of ICH GCP caused confusion to those of us who work with non-interventional studies. The glossary [...]
Real World Evidence (RWE) 101 – Non-Interventional Studies vs Market Health Research
RWE 101 - Non-Interventional Studies vs Market Health Research Key differences between a non-interventional study (NIS) and market health research include:1. Research Objective: NIS are conducted to examine real-world [...]
Real World Evidence (RWE) 101 – Real World Evidence (RWE) 101 – Audits vs Inspections
RWE 101 - Real World Evidence (RWE) 101 - Audits vs Inspections In the context of regulatory compliance for Real-World Evidence (RWE), both audits and inspections play crucial roles, [...]
Real World Evidence (RWE) 101 – A Career of Many Pathways
RWE 101 - A Career of Many Pathways Real-world evidence (RWE) refers to the information on health care that is derived from analysis of real-world data (RWD). RWE [...]
Real World Evidence (RWE) 101 – Evolution of Regulatory Affairs
RWE 101 - Evolution of Regulatory Affairs Real-world evidence (RWE) and real-world data (RWD) are increasingly influencing regulatory affairs in the biopharmaceutical and healthcare industry. This change has been [...]
Real World Evidence (RWE) 101 – Project Managers
RWE 101 - Project Managers Real-World Evidence (RWE) observational studies and clinical trials are both key elements of medical research, but they involve very different methodologies, aims, and requirements. [...]